Navigation Links
Orexigen Therapeutics Reports Business and Financial Results for the Third Quarter Ended September 30, 2013
Date:11/12/2013

igen. "We continue to expect we will receive the analysis from the DMC and complete our review by early December."

"We expect that an interim analysis that meets the pre-specified safety hurdles will enable a series of important steps in 2014 toward the global commercialization of Contrave, including potential approvals in the US and Europe, progression of partnership discussions for ex-North American Contrave rights, and the potential commercial launch of Contrave in North America by Takeda," Narachi continued.

Recent business highlights:

  • In October, Orexigen submitted the Marketing Authorization Application for Contrave to the European Medicines Agency. Cardiovascular outcomes data from the Light Study are expected to be available for the Committee for Medicinal Products for Human Use (CHMP) Day 120 List of Questions.
  • In preparation for the potential launch of Contrave, Takeda assumed from the Company the responsibility to package Contrave for commercial sale. The Company will continue to supply bulk tablets of Contrave to Takeda in accordance with the terms of the Collaboration Agreement.
  • Orexigen entered into a commercial supply agreement with Sanofi to manufacture and supply Contrave for territories outside North America.
  • Product candidates: Contrave (32 mg naltrexone sustained‐release (SR)/360 mg bupropion SR) for the treatment of obesity: In 2012, Orexigen screened more than 13,000 patients, enrolled more than 10,400 and ultimately completed recruitment of the Light Study with approximately 8,900 randomized patients. The primary objective of the double‐blind, randomized, placebo‐controlled Light Study, which Orexigen is conducting under a Special Protocol Assessment with the FDA (United States Food and Drug Administration), is to rule out excess cardiovascular risk in overweight and obese patients receiving Contrave. An interim analysis of the Light Study is anticipated by early Decem
    '/>"/>

    SOURCE Orexigen Therapeutics, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8

    Related medicine technology :

    1. Orexigen and Takeda Announce Multiple Contrave Data Presentations at the ObesityWeek Meeting in Atlanta
    2. Orexigen Therapeutics Enters Into Agreement with Sanofi to Manufacture Contrave for Territories Outside North America
    3. A Balanced Risk-Benefit Profile Will Propel Orexigen/Takedas Contrave to Become the Most Widely Used Emerging Therapy for the Treatment of Obese and Overweight Patients
    4. Orexigen Therapeutics Announces Date of Third Quarter 2013 Financial Results Conference Call and Upcoming Presentation at Credit Suisse Healthcare Conference
    5. Orexigen Therapeutics to Present at the Bank of America Merrill Lynch Global Healthcare Conference
    6. Orexigen Therapeutics Announces European Filing Strategy and Reports Business and Financial Results for the Second Quarter Ended June 30, 2013
    7. Orexigen Therapeutics to Host Second Quarter 2013 Financial Results Conference Call and Webcast
    8. Orexigen Therapeutics Announces Upcoming Clinical Data Presentations at American Diabetes Association Annual Scientific Meeting
    9. Orexigen Therapeutics to Present at the Jefferies 2013 Global Healthcare Conference
    10. Orexigen Therapeutics to Present at the UBS Global Healthcare Conference
    11. Orexigen Therapeutics Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2012
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:12/19/2014)... France , Dec. 19, 2014  Eli Lilly ... (Euronext Paris: FR0011184241 – ADOC) today announced a worldwide ... as BioChaperone Lispro, for treatment in people with type ... Adocia,s proprietary BioChaperone® technology and is currently in Phase ... BioChaperone Lispro with the goal of optimizing glucose levels ...
    (Date:12/17/2014)... 2014 Revenue and earnings above the ... and development In the past 2013/14 fiscal year ... percent to EUR 4.287 billion (last year: EUR 4.190 billion) ... to EUR 360 million. "Overall, 2013/14 was a successful fiscal ... , President and CEO of Carl Zeiss AG. "Thanks to ...
    (Date:12/17/2014)... , Dec. 17, 2014  Beamz Interactive, ... interactive music products, today announced that it has ... leading manufacturer and supplier of innovative prosthetic, orthotic ... As part of the agreement, RSL Steeper will ... solution specifically configured for use within UK residential ...
    Breaking Medicine Technology:Lilly and Adocia Announce Alliance to Co-Develop Ultra-Rapid Insulin Based on BioChaperone Technology 2Lilly and Adocia Announce Alliance to Co-Develop Ultra-Rapid Insulin Based on BioChaperone Technology 3ZEISS Asserts its Position in Difficult Environment 2Beamz Interactive, Inc. Signs UK Distribution Agreement with RSL Steeper Limited 2Beamz Interactive, Inc. Signs UK Distribution Agreement with RSL Steeper Limited 3
    ... Sutro Biopharma, a biopharmaceutical company developing both ... properties, today announced that it has appointed Trevor ... Hallam will lead Sutro,s ongoing efforts in the ... platform for the research and development of novel ...
    ... 8, 2010 /PRNewswire-Asia/ -- From the 1st to the ... developed world will meet at Vaccine World Summit in ... in partnership with DCVMN (Developing Countries Vaccine Manufacturers Network). ... global public health challenges including appropriate pandemic surveillance programs, ...
    Cached Medicine Technology:Sutro Biopharma Appoints Trevor Hallam, Ph.D., as Chief Scientific Officer 2World Vaccine Leaders to Meet in New Delhi India to Tackle Global Public Health Challenges 2
    (Date:12/20/2014)... December 21, 2014 BambooIndustry.com is ... Recently, the business has announced its bamboo flooring ... the best material from certified suppliers, and offers ... customers worldwide. In the current promotion, all customers ... off, when they say they know BambooIndustry.com from ...
    (Date:12/20/2014)... December 20, 2014 Dress company LunaDress has ... and announced its Christmas Sale, offering big discounts on all ... girl has an idea to own a perfect wedding gown. ... your wedding dress, then come to LunaDress. Many different wedding ... you. Visit our website now and enjoy the current special ...
    (Date:12/20/2014)... VogueQueen.com, a leading wedding dress wholesaler and retailer, has ... 2015. Great discounts are now offered on all of ... a discount, up to 80% off, when they place ... 2015. , VogueQueen.com has recently released its new arrival ... Many customers worldwide like VogueQueen’s special designs which feature ...
    (Date:12/20/2014)... 20, 2014 Atore, Inc, (San Francisco, ... launched first birthday focused portal on December 17th, 2014. ... launched in both US and Japan. , MERRY BIRTHDAY ... http://merrybirthday.net/message/ , MERRY BIRTHDAY MESSAGE is part ... the world. , Features, Choose from thousands of stock ...
    (Date:12/20/2014)... Columbus, OH (PRWEB) December 20, 2014 ... contend they suffered uncontrollable bleeding and other ... District Court, Eastern District of Louisiana for coordinated pretrial ... Panel on Multidistrict Litigation (JPML) issued an order Friday ... tag-along actions pending in 22 federal courts to the ...
    Breaking Medicine News(10 mins):Health News:Eco-friendy Bamboo Flooring Manufacturer BambooIndustry.com Introduces Its Bamboo Flooring Promotion for 2015 2Health News:2015 Collection of Wedding Dresses from LunaDress Online on Sale Now 2Health News:VogueQueen Big Sale Online For The Coming 2015 2Health News:Atore, Inc. Releasing the First Birthday Portal 2Health News:Xarelto Bleeding Lawsuits Consolidated To Louisiana Federal Court For Multi-District Litigation Reports Wright & Schulte LLC 2Health News:Xarelto Bleeding Lawsuits Consolidated To Louisiana Federal Court For Multi-District Litigation Reports Wright & Schulte LLC 3Health News:Xarelto Bleeding Lawsuits Consolidated To Louisiana Federal Court For Multi-District Litigation Reports Wright & Schulte LLC 4
    ... patients could benefit from similar,improvements, DALLAS, ... article published today, "An organized approach to ... presented the first,head-to-head comparison of quality medical ... Disease (GWTG-CAD) hospitals vs. other US,hospitals not ...
    ... PITTSBURGH, Sept. 8 Mylan Inc. (NYSE: ... to market and other,conditions, $400 million principal amount ... offering to qualified institutional buyers pursuant,to Rule 144A ... (the "Securities,Act"). Mylan also expects to grant the ...
    ... States Agency for International Development (USAID) has awarded the ... at Chapel Hill up to $181 million to continue ... largest ever received by UNC. , The award funds ... child health, nutrition and HIV/AIDS programs around the world. ...
    ... Menopausal women who take hormones face greater chance of ... -- Women who take hormones to relieve symptoms of ... gastroesophageal reflux disease (GERD). , Also, women who use ... cancer and osteoporosis, also have a higher risk of ...
    ... Sept. 8 The nation faces,challenges in utilizing ... health, according to a NASA-sponsored report issued Monday,by ... report examines the computer-based decision support tools that ... in areas such as,agricultural productivity, air quality, renewable ...
    ... Sunday, Sept 14, 2008, WHERE: Moscone South Convention Center ... Francisco, CA 94103, and, ... 55 4th Street San Francisco, CA 94103, ... Nickols (916) 704-8965, WHAT: Approximately 15,000 dentists and dental professionals are ...
    Cached Medicine News:Health News:Hospitals Participating in Get With The Guidelines(SM) Program Follow Heart Attack Treatment Guidelines Better Than Others 2Health News:Mylan to Offer $400 Million in Cash Convertible Notes 2Health News:Mylan to Offer $400 Million in Cash Convertible Notes 3Health News:UNC receives record $181 million grant to evaluate health, poverty and gender programs worldwide 2Health News:HRT Use Raises Risk of Stomach Trouble 2Health News:HRT Use Raises Risk of Stomach Trouble 3Health News:Report Explores Use of Earth Data to Support National Priorities 2Health News:Report Explores Use of Earth Data to Support National Priorities 3Health News:Renowned Dentists to Present Latest on Dental Innovations 2Health News:Renowned Dentists to Present Latest on Dental Innovations 3
    ... Bledsoe Sport & Sport Max patellofemoral knee ... and/or collateral injuries. Patients with minor knee ... can benefit from added support to prevent ... designs to provide the right kind of ...
    ... Brace gives fracture treatment patients maximum support ... brace features the the Bledsoe Multi-Centric Hinge, ... and positively locks at any angle within ... slots, the Bledsoe Multi-Centric Hinge anatomically tracks ...
    ... The Bledsoe Revolution ... for speed fitting under ... frees the surgeon or ... time-consuming post-op fitting and ...
    The Bledsoe Post-Op Knee Brace is designed to provide maximum protection without sacrificing comfort and quick, easy application....
    Medicine Products: